Effect of Doxycycline on clinical improvement and outcome in patients with COVID-19

Evaluation of effectiveness and safety of Doxycycline in combination with standard treatment on clinical improvement and outcome of Covid-19 patients: a clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201117049427N1

Enrollment

180

Registered

2022-08-08

Start date

2020-12-05

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid 19. Coronavirus infection, unspecified

Interventions

Intervention 1: Intervention group: In addition to the national standard protocol and supportive therapies, they are treated with doxycycline capsules manufactured by Pars Behroozan company at a dose

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Age higher than 18 years Definitive diagnosis of Covid 19 Having informed satisfaction

Exclusion criteria

Exclusion criteria: Allergy to Doxycycline Chronic liver disease Chronic kidney disease History of lupus History of porphyria Pregnancy and lactation

Design outcomes

Primary

Measure	Time frame
Duration of hospitalization. Timepoint: Before the intervention and 5 days after the intervention. Method of measurement: Checklist.;ICU admission. Timepoint: Before the intervention and 5 days after the intervention. Method of measurement: Checklist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElnaz Sarkheyl

Iran University of Medical Sciences

elnazsarkheyl@gmail.com+98 21 5621 3583

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026